In the last trading session, 1.27 million shares of the Aquestive Therapeutics Inc (NASDAQ:AQST) were traded, and its beta was 2.69. Most recently the company’s share price was $2.73, and it changed around $0.08 or 3.02% from the last close, which brings the market valuation of the company to $248.91M. AQST currently trades at a discount to its 52-week high of $6.23, offering almost -128.21% off that amount. The share price’s 52-week low was $2.24, which indicates that the current value has risen by an impressive 17.95% since then.
Aquestive Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.11. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended AQST as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Aquestive Therapeutics Inc is expected to report earnings per share of -0.13 for the current quarter.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Instantly AQST has showed a green trend with a performance of 3.02% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.92 on recent trading dayincreased the stock’s daily price by 6.51%. The company’s shares are currently down -23.31% year-to-date, but still down -2.33% over the last five days. On the other hand, Aquestive Therapeutics Inc (NASDAQ:AQST) is -9.60% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 72.7% from its current value. Analyst projections state that AQST is forecast to be at a low of $10 and a high of $10.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
The year-over-year growth rate is expected to be 13.67%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 13.11M in revenue for the current quarter. 6 analysts expect Aquestive Therapeutics Inc to make 12.9M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 13.21M and 12.05M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -0.71%. Forecasts for the next quarter put sales growth at 7.03%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 46.61%.
AQST Dividends
Aquestive Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
BLACKROCK INC., with 7.4099% or 5.45 million shares worth $14.18 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.4 shares worth $6.56 million, making up 2.64% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.02 shares worth around $5.5 million, which represents about 2.21% of the total shares outstanding.
